OUR PIPELINE

Focusing on making a difference in rare diseases with significant unmet need

Program Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3

Sparsentan1

IgAN

Sparsentan

FSGS

CDCA2

CTX

Pegtibatinase (TVT-058)3

HCU

ALGS Collaboration

ALGS

THERAPEUTIC AREAS

1 On February 17, 2023, Travere announced that the FDA granted approval of sparsentan under the accelerated pathway for the reduction of proteinuria in IgAN. Read the press release>

2 CDCA is not indicated for CTX, but has received a medical necessity determination in the US by the FDA for CTX. Travere Therapeutics is conducting a Phase 3 clinical trial to examine the safety and efficacy of CDCA (Chenodal®) for the treatment of CTX.

3 Pegtibatinase (TVT-058) is currently in a Phase 1/2 clinical study.

FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; CTX: cerebrotendinous xanthomatosis; HCU: classical homocystinuria; ALGS: Alagille syndrome